P
Paul G. Richardson
Researcher at Harvard University
Publications - 1631
Citations - 174221
Paul G. Richardson is an academic researcher from Harvard University. The author has contributed to research in topics: Multiple myeloma & Bortezomib. The author has an hindex of 183, co-authored 1533 publications receiving 155912 citations. Previous affiliations of Paul G. Richardson include Broomfield Hospital & Dartmouth College.
Papers
More filters
Journal ArticleDOI
Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone
Jean-Luc Harousseau,Antonio Palumbo,Paul G. Richardson,Rudolf Schlag,Meletios A. Dimopoulos,Ofer Shpilberg,Martin Kropff,Alain Kentos,Michele Cavo,Anatoly Golenkov,Mieczysław Komarnicki,Maria-Victoria Mateos,Dixie-Lee Esseltine,Andrew Cakana,Kevin Liu,William Deraedt,Helgi van de Velde,Jesús F. San Miguel +17 more
TL;DR: Results highlight that CR is an important treatment goal and support prolonged VMP therapy to achieve maximal response and highlight the prognostic impact of response on time-to-event parameters in the intent- to-treat population.
Journal ArticleDOI
The Genome of the Obligately Intracellular Bacterium Ehrlichia canis Reveals Themes of Complex Membrane Structure and Immune Evasion Strategies
Kostantinos Mavromatis,C. Kuyler Doyle,Athanasios Lykidis,Natalia Ivanova,M. P. Francino,Patrick S. G. Chain,Patrick S. G. Chain,Maria W. Shin,Maria W. Shin,Stephanie Malfatti,Stephanie Malfatti,Frank W. Larimer,Alex Copeland,J. C. Detter,Miriam Land,Paul G. Richardson,Xue Jie Yu,David H. Walker,Jere W. McBride,Nikos C. Kyrpides +19 more
TL;DR: Ehrlichia canis, a small obligately intracellular, tick-transmitted, gram-negative, α-proteobacterium, is the primary etiologic agent of globally distributed canine monocytic ehrlichiosis.
Journal ArticleDOI
Clinical and Translational Studies of a Phase II Trial of the Novel Oral Akt Inhibitor Perifosine in Relapsed or Relapsed/Refractory Waldenström's Macroglobulinemia
Irene M. Ghobrial,Aldo M. Roccaro,Fangxin Hong,Edie Weller,Nancy Rubin,Renee Leduc,Meghan Rourke,Stacey Chuma,Antonio Sacco,Xiaoying Jia,Feda Azab,Abdel Kareem Azab,Scott J. Rodig,Diane Warren,Brianna Harris,Lyuba Varticovski,Peter Sportelli,Xavier Leleu,Kenneth C. Anderson,Paul G. Richardson +19 more
TL;DR: Perifosine resulted in at least a minimal response in 35% of patients and a median progression-free survival of 12.6 months in patients with relapsed or relapsed/refractory WM, as well as in vivo inhibition of pGSK activity.
Journal ArticleDOI
Novel therapeutic approaches for multiple myeloma.
TL;DR: Treatment strategies which target mechanisms whereby MM cells grow and survive in the bone marrow, including thalidomide and its potent immunomodulatory derivatives and proteasome inhibitor PS‐341, can overcome classical drug resistance in preclinical and early clinical studies.
Journal ArticleDOI
The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma.
Ruben Niesvizky,Paul G. Richardson,S. Vincent Rajkumar,Morton Coleman,Laura Rosiñol,Pieter Sonneveld,Michael W. Schuster,David Irwin,Edward A. Stadtmauer,Thierry Facon,Jean Luc Harousseau,Anthony Boral,Dixie Lee Esseltine,Kenneth C. Anderson,Joan Bladé +14 more
TL;DR: Bortezomib had substantial activity in relapsed myeloma patients; CR may be a surrogate marker for significant clinical benefit with bortzomib.